表紙
市場調査レポート

家族性乳び血症 (I型高リポ蛋白血症)  - パイプライン製品の分析

Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 321925
出版日 ページ情報 英文 59 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
家族性乳び血症 (I型高リポ蛋白血症)  - パイプライン製品の分析 Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Pipeline Review, H2 2015
出版日: 2015年11月18日 ページ情報: 英文 59 Pages
概要

家族性乳び血症 (I型高リポ蛋白血症)は、血漿中のトリグリセド分解酵素であるリポ蛋白リパーゼが遺伝的に不足している状況です。膵炎による腹痛、発疹性黄色腫の出現や、下肢の麻痺・記憶喪失といった神経障害が症状として挙げられます。

当レポートでは、家族性乳び血症 (I型高リポ蛋白血症) に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

家族性乳び血症 (I型高リポ蛋白血症) の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 後期段階の製品
  • 臨床段階の製品
  • 治療段階が不明の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Aegerion Pharmaceuticals, Inc.
  • Catabasis Pharmaceuticals, Inc.
  • Isis Pharmaceuticals, Inc.
  • Novartis AG
  • uniQure N.V.

治療薬の評価

  • 単独療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • alipogene tiparvovec
  • CAT-2003
  • ISIS-APOCIIIRx
  • lomitapide mesylate
  • pradigastat sodium

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7394IDB

Summary

Global Markets Direct's, 'Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Pipeline Review, H2 2015', provides an overview of the Familial Chylomicronemia (Type I Hyperlipoproteinemia)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Familial Chylomicronemia (Type I Hyperlipoproteinemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Familial Chylomicronemia (Type I Hyperlipoproteinemia) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Familial Chylomicronemia (Type I Hyperlipoproteinemia)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Familial Chylomicronemia (Type I Hyperlipoproteinemia) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Familial Chylomicronemia (Type I Hyperlipoproteinemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Familial Chylomicronemia (Type I Hyperlipoproteinemia) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Familial Chylomicronemia (Type I Hyperlipoproteinemia)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Familial Chylomicronemia (Type I Hyperlipoproteinemia) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Familial Chylomicronemia (Type I Hyperlipoproteinemia) Overview
  • Therapeutics Development
  • Therapeutics Development
    • Pipeline Products for Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Overview
    • Pipeline Products for Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Comparative Analysis
  • Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Therapeutics under Development by Companies
  • Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Unknown Stage Products
  • Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Products under Development by Companies
  • Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Companies Involved in Therapeutics Development
    • Aegerion Pharmaceuticals, Inc.
    • Catabasis Pharmaceuticals, Inc.
    • CymaBay Therapeutics, Inc.
    • Kadmon Corporation, LLC
    • Novartis AG
  • Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CAT-2003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KD-026 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • lomitapide mesylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MBX-8025 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pradigastat sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • volanesorsen sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Recent Pipeline Updates
  • Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Product Development Milestones
    • Featured News & Press Releases
      • Jul 06, 2015: Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen for the Treatment of Familial Chylomicronemia Syndrome
      • Dec 03, 2014: ISIS-APOCIII Rx Phase 2 Study in Patients with Familial Chylomicronemia Published in the New England Journal of Medicine
      • Aug 28, 2014: Isis Pharmaceuticals Initiates Phase 3 Study of ISIS-APOCIII Rx in Patients with FCS
      • May 02, 2014: Catabasis Demonstrates CAT-2003 Lowers Fed and Fasting Triglycerides in Studies Presented at Lipid Conferences
      • May 02, 2014: Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx in Patients with Familial Chylomicronemia
      • Apr 25, 2014: Catabasis to Present CAT-2003 Data at Upcoming Lipid Conferences
      • Mar 31, 2014: Isis Reports Final Phase 2 Data On ISIS-APOCIII Rx In Patients With High Triglycerides Taking Fibrates
      • Jan 13, 2014: Isis Announces Positive Decision On European Orphan Drug Designation For ISIS-APOCIII Rx
      • Nov 18, 2013: Isis Pharmaceuticals Reports Fifth Positive Phase 2 Data Set for ISIS-APOCIII Rx Showing Significant Reductions in Triglyceride and ApoC-III Levels
      • Sep 22, 2013: Isis Pharmaceuticals to Conduct Webcast and Conference Call to Discuss ISIS-APOCIII Rx Phase 2 Data
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Familial Chylomicronemia (Type I Hyperlipoproteinemia), H2 2015
  • Number of Products under Development for Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Unknown Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Pipeline by Aegerion Pharmaceuticals, Inc., H2 2015
  • Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2015
  • Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Pipeline by CymaBay Therapeutics, Inc., H2 2015
  • Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Pipeline by Kadmon Corporation, LLC, H2 2015
  • Familial Chylomicronemia (Type I Hyperlipoproteinemia) - Pipeline by Novartis AG, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Familial Chylomicronemia (Type I Hyperlipoproteinemia) Therapeutics - Recent Pipeline Updates, H2 2015

List of Figures

  • Number of Products under Development for Familial Chylomicronemia (Type I Hyperlipoproteinemia), H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Targets, H2 2015
  • Number of Products by Stage and Targets, H2 2015
  • Number of Products by Mechanism of Actions, H2 2015
  • Number of Products by Stage and Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top